Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lynda Tran

Nurse Practitioner, Primary Care Huntington Beach, CA Nurse Practitioner

NPI 1942776240 CMS profile 10648960

19582 Beach Blvd Ste 212, Huntington Beach, CA 92605

Open in the dashboard

General payments

$15,663

243 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lynda Tran of Huntington Beach, CA is reported in the CMS Open Payments database as having received $15,663 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,586 41
2024 General $5,109 75
2023 General $2,959 39
2022 General $1,900 17
2021 General $3,110 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lynda Tran
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Lynda Tran were reported at $2,586. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Lynda Tran Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,110 $137 $39–$445 $132
2022 $1,900 $139 $44–$421 $149
2023 $2,959 $163 $53–$481 $160
2024 $5,109 $176 $54–$511 $164
2025 $2,586 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,073 48 payments
  2. E.R. Squibb & Sons, L.L.C. $1,307 15 payments
  3. Astellas Pharma US Inc $1,051 13 payments
  4. AstraZeneca Pharmaceuticals LP $933 8 payments
  5. GlaxoSmithKline, LLC. $866 8 payments
  6. Merck Sharp & Dohme Corporation $797 18 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $781 14 payments
  8. Celgene Corporation $615 12 payments
  9. Exelixis Inc. $581 13 payments
  10. Daiichi Sankyo Inc. $493 13 payments
  11. Other $5,165 81 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,324 239 payments
  2. Education $339 4 payments
Products named General payments · program years 2021–2025
  1. DARZALEX $1,616 23 payments
  2. TECVAYLI $1,421 14 payments
  3. CARVYKTI $1,266 9 payments
  4. RYBREVANT $862 7 payments
  5. REBLOZYL $777 6 payments
  6. IMBRUVICA $635 15 payments
  7. LIBTAYO $533 10 payments
  8. KEYTRUDA $517 14 payments
  9. CALQUENCE $492 4 payments
  10. LYNPARZA $463 12 payments
  11. Other $10,090 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

353

Median for Nurse Practitioner: 389

Drug cost

$1,660,154

Median for Nurse Practitioner: $21,885

Branded share of claims

64.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nubeqa Darolutamide Brand 42 $515,834
Erleada Apalutamide Brand 30 $446,103
Xtandi Enzalutamide Brand 24 $338,152
Orgovyx Relugolix Brand 132 $337,993
Abiraterone Acetate Generic 12 $21,032
Clindamycin Phosphate Generic 11 $304
Ondansetron Hcl Generic 16 $246
Prednisone Generic 49 $204
Levothyroxine Sodium Generic 13 $131
Gabapentin Generic 13 $106

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$27,206

Medicare's payments for the services billed

Medicare patients

162

Average age 75

Services billed

436

34 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 73%
Ischemic heart disease 35%
Arthritis 35%
Diabetes 25%
Chronic kidney disease 25%
Depression 24%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DARZALEX
  • Janssen Biotech, Inc. $548
$548 — —
TECVAYLI
  • Janssen Biotech, Inc. $450
$450 — —
OJJAARA
  • GlaxoSmithKline, LLC. $250
$250 — —
Orserdu
  • Stemline Therapeutics Inc. $245
$245 — —
Padcev
  • Astellas Pharma US Inc $124
  • PFIZER INC. $121
$245 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record